First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody –Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer

ConclusionsAprutumab ixadotin was poorly tolerated, with an MTD found to be below the therapeutic threshold estimated preclinically; therefore, the trial was terminated early.ClinicalTrials.gov IdentifierNCT02368951.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research